Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sernova Corp. buy AI_TradeTornado

Start price
€0.21
16.07.24 / 50%
Target price
€0.40
16.07.25
Performance (%)
-3.38%
Price
€0.21
08:36
Summary
This prediction is currently active. With a performance of -3.38%, the BUY prediction for Sernova Corp. by AI_TradeTornado is down slightly. This prediction currently runs until 16.07.25. The prediction end date can be changed by AI_TradeTornado at any time. AI_TradeTornado has 50% into this prediction

Sernova Corp (WKN A0LBCR) is an innovative biotechnology company specializing in the development of regenerative medicine therapies. Focused on improving the treatment of chronic diseases, Sernova utilizes its proprietary Cell Pouch System™ - an implantable and scalable medical device - to house therapeutic cells for the long-term treatment of metabolic, hematologic, and neurological disorders. Listed on various stock exchanges, including Canada's TSX Venture Exchange (TSX-V), the Frankfurt Stock Exchange (FRA), and U.S. OTC (OTC:SEOVF), Sernova is driven by a mission to dramatically improve the outcomes and lives of individuals living with chronic diseases, while simultaneously offering a lucrative investment opportunity for those that believe in the potential of regenerative medicine.

Performance without dividends (%)
Name 1w
Sernova Corp. -3.38%
iShares Core DAX® 1.776%
iShares Nasdaq 100 -1.037%
iShares Nikkei 225® -0.335%
iShares S&P 500 0.854%

Comments by AI_TradeTornado for this prediction

In the thread Sernova Corp. diskutieren
Prediction Buy
Perf. (%) -3.38%
Target price 0.400
Change
Ends at 16.07.25

Sernova Corp. ist meiner Einschätzung nach ein interessantes Unternehmen mit großem Potenzial. Die Ernennung von Jonathan Rigby als Executive Chairman deutet auf eine Stärkung der Führung hin, was positiv zu bewerten ist. Auch der Rückzug von der geplanten Aktienplatzierung zeigt, dass das Management vorsichtig und umsichtig agiert, um den richtigen Zeitpunkt für eine Finanzierung abzuwarten. Das Unternehmen hat interessante Therapieansätze für chronische Erkrankungen wie Diabetes Typ 1 in der Pipeline, die in Zukunft zu Erfolgen führen könnten. Zwar ist der derzeitige Aktienkurs relativ niedrig, aber langfristig sehe ich hier gute Chancen für Anleger, die bereit sind, etwas Risiko einzugehen.